Valsartan therapy in heart failure after myocardial infarction: the role of endothelial dependent vasorelaxation
- PMID: 18091589
- DOI: 10.1097/FJC.0b013e318159378b
Valsartan therapy in heart failure after myocardial infarction: the role of endothelial dependent vasorelaxation
Abstract
Angiotensin II receptor blockade (ARB) increases vasorelaxation in heart failure by enhancing endothelial nitric oxide (NO). To determine the effects of valsartan on NO-mediated peripheral vascular function after myocardial infarction (MI), we treated adult male Sprague-Dawley rats immediately after MI with valsartan for 3 weeks (sham, n = 10; MI, n = 11) and 6 weeks (sham, n = 6; MI, n = 8). At both time points, valsartan lowered (P < 0.05) left ventricular (LV) systolic pressure (103 +/- 4 and 107 +/- 4 vs. 93 +/- 3 and 85 +/- 4 mm Hg, respectively) and LV end-diastolic pressure (25 +/- 1 and 25 +/- 2 to 13 +/- 2 and 18 +/- 3 mm Hg, respectively). Valsartan lowered (P < 0.05) LV dP/dt only at 6 weeks (4676 +/- 168 and 4503 +/- 232 vs. 4539 +/- 281 and 3372 +/- 417 mm Hg/sec); valsartan shortened (P < 0.05) the time constant of LV relaxation or tau only at 3 weeks (24.2 +/- 1.8 and 26.5 +/- 2.3 vs. 20.1 +/- 0.7 and 23.8 +/- 1.4 msec). At 6 weeks, the vasorelaxation response to acetycholine in aortic rings was decreased (P < 0.05) with MI and improved at acetycholine doses (10, 10, and 10; P < 0.06) with valsartan. Endothelial nitric oxide synthase (eNOS) protein was undetectable in aortic tissue from valsartan treated rats or from aortic tissue incubated with valsartan (2.5, 25, and 50 mg/mL). These data suggest that valsartan improves cardiac function after MI by modulating LV remodeling, decreasing LV end-diastolic pressure, and enhancing both LV diastolic and endothelial function. These effects are mediated, in part, by NO but upregulation of eNOS may not be required for improved systemic endothelial function in heart failure.
Similar articles
-
Angiotensin subtype 1 rReceptor (AT1) blockade improves vasorelaxation in heart failure by up-regulation of endothelial nitric-oxide synthase via activation of the AT2 receptor.J Pharmacol Exp Ther. 2003 Dec;307(3):1171-8. doi: 10.1124/jpet.103.054916. Epub 2003 Oct 14. J Pharmacol Exp Ther. 2003. PMID: 14560036
-
AT2 receptor mediates the cardioprotective effects of AT1 receptor antagonist in post-myocardial infarction remodeling.Life Sci. 2006 Dec 3;80(1):82-8. doi: 10.1016/j.lfs.2006.08.033. Epub 2006 Sep 6. Life Sci. 2006. PMID: 17023005
-
Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction.Circulation. 2008 Aug 19;118(8):818-27. doi: 10.1161/CIRCULATIONAHA.107.717702. Epub 2008 Aug 4. Circulation. 2008. PMID: 18678774
-
New basic science initiatives with the angiotensin II receptor blocker valsartan.J Renin Angiotensin Aldosterone Syst. 2000 Jun;1(2 Suppl):S3-5. doi: 10.3317/jraas.2000.052. J Renin Angiotensin Aldosterone Syst. 2000. PMID: 17199210 Review.
-
Potential novel pharmacological therapies for myocardial remodelling.Cardiovasc Res. 2009 Feb 15;81(3):519-27. doi: 10.1093/cvr/cvn317. Epub 2008 Nov 19. Cardiovasc Res. 2009. PMID: 19019834 Review.
Cited by
-
Sacubitril-valsartan improves conduit vessel function and functional capacity and reduces inflammation in heart failure with reduced ejection fraction.J Appl Physiol (1985). 2021 Jan 1;130(1):256-268. doi: 10.1152/japplphysiol.00454.2020. Epub 2020 Nov 19. J Appl Physiol (1985). 2021. PMID: 33211601 Free PMC article.
-
Endothelial Dysfunction: Clinical Implications in Cardiovascular Disease and Therapeutic Approaches.J Korean Med Sci. 2015 Sep;30(9):1213-25. doi: 10.3346/jkms.2015.30.9.1213. Epub 2015 Aug 13. J Korean Med Sci. 2015. PMID: 26339159 Free PMC article. Review.
-
Guidelines for translational research in heart failure.J Cardiovasc Transl Res. 2015 Feb;8(1):3-22. doi: 10.1007/s12265-015-9606-8. Epub 2015 Jan 21. J Cardiovasc Transl Res. 2015. PMID: 25604959
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical